Skip to main content
SpringerLink
Log in

Cytokines in Hematopoietic Stem Cell Transplantation

  • Chapter
Cytokines and Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 126))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Powles RL, Mehta J. The future of bone marrow transplantation. In: Atkinson K, ed. Clinical Bone Marrow Transplantation: A Reference Textbook. Cambridge, Cambridge University Press, 1994; 736–740.

    Google Scholar 

  2. Mehta J, Powles R. The future of bone marrow transplantation. In: Atkinson K, ed. Clinical Bone Marrow and Blood Stem Cell Transplantation, second edition. Cambridge, Cambridge University Press, 2000:1457–1465.

    Google Scholar 

  3. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80:2964–2968.

    PubMed  CAS  Google Scholar 

  4. Hill GR, Ferrara JLM. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95:2754–2759.

    PubMed  CAS  Google Scholar 

  5. Mehta J, Powles R, Treleaven J, Kulkarni S, Singhal S. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients. Bone Marrow Transplant 1997; 20:129–135.

    Article  PubMed  CAS  Google Scholar 

  6. Kijrbling M. Mobilization regimens for harvesting autologous and allogeneic peripheral blood stem cells. In: Atkinson K, Champlin R, Ritz J, Fibbe WE, Ljungman P, Brenner MK, eds. Clinical Bone Marrow and Blood Stem Cell Transplantation, 3rd ed. Cambridge, Cambridge University Press, 2004: 383–403.

    Google Scholar 

  7. Ritchie DS, Grigg AP. Use of hematopoietic growth factors, interleukins, and interferons following autologous hematopoietic stem cell transplantation. In: Atkinson K, Champlin R, Ritz J, Fibbe WE, Ljungman P, Brenner MK, eds. Clinical Bone Marrow and Blood Stem Cell Transplantation, 3rd ed. Cambridge, Cambridge University Press, 2004: 479–492.

    Google Scholar 

  8. Ritchie DS, Grigg A. Use of hematopoietic growth factors following allogeneic hematopoietic stem cell transplantation. In: Atkinson K, Champlin R, Ritz J, Fibbe WE, Ljungman P, Brenner MK, eds. Clinical Bone Marrow and Blood Stem Cell Transplantation, 3rd ed. Cambridge, Cambridge University Press, 2004: 493–504.

    Google Scholar 

  9. Thomas J, Liu F, Link DC. Mechanisms of mobilization of hematopoietic progenitors with granulocyte colony-stimulating factor. Curr Opin Hematol 2002; 9:183–189.

    Article  PubMed  Google Scholar 

  10. Papayannopoulou T. Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. Blood 2004; 103:1580–1585.

    Article  PubMed  CAS  Google Scholar 

  11. Juttner CA, To LB, Haylock DN, Branford A, Kimber RJ. Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy. Br J Haematol 1985; 61:739–745.

    PubMed  CAS  Google Scholar 

  12. Kessinger A, Bierman PJ, Vose JM, Armitage JO. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease [Erratum: Blood 1991; 78:3330]. Blood 1991; 77:2322–2325.

    PubMed  CAS  Google Scholar 

  13. Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339:640–644.

    Article  PubMed  CAS  Google Scholar 

  14. Elias AD, Ayash L, Anderson KC, et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79:3036–3044.

    PubMed  CAS  Google Scholar 

  15. Kotasek D, Shepherd KM, Sage RE, et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9:11–17.

    PubMed  CAS  Google Scholar 

  16. Carella AM, Pollicardo N, Pungolino E, Raffo MR, Podesta M, Ferrero R et al. Mobilization of cytogenetically ‘normal’ blood progenitors cells by intensive conventional chemotherapy for chronic myeloid and acute lymphoblastic leukemia. Leuk Lymphoma 1993; 9:477–483.

    Article  PubMed  CAS  Google Scholar 

  17. Demirer T, Ayli M, Ozcan M, et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002; 116:468–474.

    Article  PubMed  CAS  Google Scholar 

  18. Andre M, Baudoux E, Bron D, et al. Phase III randomized study comparing 5 or 10 □ g per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 2003; 43:50–57.

    Article  PubMed  CAS  Google Scholar 

  19. Haas R, Ho AD, Bredthauer U, et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 1990; 18:94–98.

    PubMed  CAS  Google Scholar 

  20. Chao NJ, Schriber JR, Grimes K, et al. Granulocyte colony-stimulating factor &quote;mobilized&quote; peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81:2031–2035.

    PubMed  CAS  Google Scholar 

  21. Winter JN, Lazarus HM, Rademaker A, et al. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol 1996; 14:277–286.

    PubMed  CAS  Google Scholar 

  22. Kroger N, Zeller W, Fehse N, et al. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients. Br J Haematol 1998; 102:1101–1106.

    Article  PubMed  CAS  Google Scholar 

  23. Gazitt Y, Freytes CO, Callander N, et al. Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. J Hematother 1999; 8:173–183.

    Article  PubMed  CAS  Google Scholar 

  24. Mehta J, Mijovic A, Powles R, et al. Myelosuppressive chemotherapy to mobilize normal stem cells in chronic myeloid leukemia. Bone Marrow Transplant 1996; 17:25–29.

    PubMed  CAS  Google Scholar 

  25. Mehta J, Powles R, Singhal S, et al. High-dose hydroxyurea and G-CSF to collect Philadelphia-negative cells in chronic myeloid leukemia. Leuk Lymphoma 1996; 23:107–111.

    PubMed  CAS  Google Scholar 

  26. Singhal S. High-dose therapy and autologous transplantation. In: Mehta J, Singhal S, eds. Myeloma. London, Martin Dunitz, 2002:327–347.

    Google Scholar 

  27. Singhal S, Powles R, Treleaven J, et al. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106 CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000; 26:489–496.

    Article  PubMed  CAS  Google Scholar 

  28. Singhal S, Powles R, Kulkami S, et al. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation. Bone Marrow Transplant 2000; 25:501–505.

    Article  PubMed  CAS  Google Scholar 

  29. Grigg AP, Roberts AW, Raunow H, et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86:4437–4445.

    PubMed  CAS  Google Scholar 

  30. Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355:1231–1237.

    Article  PubMed  CAS  Google Scholar 

  31. Anderlini P, Chan FA, Körbling M, et al. Long-term follow-up of peripheral blood progenitor cell donors: no evidence for increased risk of leukemia development. Bone Marrow Transplant 2002; 30:661–663.

    Article  PubMed  CAS  Google Scholar 

  32. Morton J, Hutchins C, Durrant S. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001; 98:3186–3191.

    Article  PubMed  CAS  Google Scholar 

  33. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344:175–181.

    Article  PubMed  CAS  Google Scholar 

  34. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19:3685–3691.

    PubMed  CAS  Google Scholar 

  35. Przepiorka D, Anderlini P, Saliba R, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98:1695–1700.

    Article  PubMed  CAS  Google Scholar 

  36. Mehta J, Singhal S. Chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell transplantation: a little methotrexate goes a long way. J Clin Oncol 2002; 20:603–604.

    Article  PubMed  CAS  Google Scholar 

  37. Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients [Erratum: Lancet 1996; 347:914]. Lancet 1996; 347:353–357.

    Article  PubMed  CAS  Google Scholar 

  38. Mehta J, Powles R, Horton C, Treleaven J, Singhal S. Factors affecting engraftment and hematopoietic recovery after unpurged autografting in acute leukemia. Bone Marrow Transplant 1996; 18:319–324.

    PubMed  CAS  Google Scholar 

  39. Gisselbrecht C, Prentice HG, Bacigalupo A, et al. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation [Erratum: Lancet 1994; 343:804]. Lancet 1994; 343:696–700.

    Article  PubMed  CAS  Google Scholar 

  40. Stahel RA, Jost LM, Cemy T, et al. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994; 12:1931–1938.

    PubMed  CAS  Google Scholar 

  41. Schmitz N, Dreger P, Zander AR, et al. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995; 15:261–266.

    PubMed  CAS  Google Scholar 

  42. Linch DC, Milligan DW, Winfield DA, et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol 1997; 99:933–938.

    Article  PubMed  CAS  Google Scholar 

  43. Linch DC, Scarffe H, Proctor S, et al. Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 1993; 11:307–311.

    PubMed  CAS  Google Scholar 

  44. Bolwell B, Goormastic M, Dannley R, et al. G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16 micrograms/kg/day. Bone Marrow Transplant 1997; 19:215–219.

    Article  PubMed  CAS  Google Scholar 

  45. Stahel RA, Jost LM, Honegger H, Betts E, Goebel ME, Nagler A. Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas. J Clin Oncol 1997; 15:1730–1735.

    PubMed  CAS  Google Scholar 

  46. Torres-Gomez A, Jimenez MA, Alvarez MA, et al. Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation. A prospective randomized study. Ann Hematol 1995; 71:65–70.

    PubMed  CAS  Google Scholar 

  47. Faucher C, Le Corroller AG, Chabannon C, et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study. Bone Marrow Transplant 1996; 17:533–536.

    PubMed  CAS  Google Scholar 

  48. Bolwell BJ, Pohlman B, Andresen S, et al. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplant 1998; 21:369–373.

    Article  PubMed  CAS  Google Scholar 

  49. Verma A, Pedicano J, Trifilio S, et al. How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients? Bone Marrow Transplant 2004 (In press).

    Google Scholar 

  50. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324:1773–1778.

    Article  PubMed  CAS  Google Scholar 

  51. Link H, Boogaerts MA, Carella AM, et al. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992; 80:2188–2195.

    PubMed  CAS  Google Scholar 

  52. Gorin NC, Coiffier B, Hayat M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial. Blood 1992; 80:1149–1157.

    PubMed  CAS  Google Scholar 

  53. Greenberg P, Advani R, Keating A, et al. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 1996; 18:1057–1064.

    PubMed  CAS  Google Scholar 

  54. Cortelazzo S, Viero P, Bellavita P, et al. Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma. J Clin Oncol 1995; 13:935–941.

    PubMed  CAS  Google Scholar 

  55. Brice P, Marolleau JP, Pautier P, et al. Hematologic recovery and survival of lymphoma patients after autologous stem-cell transplantation: comparison of bone marrow and peripheral blood progenitor cells. Leuk Lymphoma 1996; 22:449–456.

    PubMed  CAS  Google Scholar 

  56. Ojeda E, Garcia Bustos J, Aguado M, et al. A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults. Bone Marrow Transplant 1999; 24:601–607.

    Article  PubMed  CAS  Google Scholar 

  57. Spitzer G, Adkins DR, Spencer V, et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994; 12:661–670.

    PubMed  CAS  Google Scholar 

  58. Legros M, Fleury J, Bay JO, et al. rhGM-CSF vs placebo following rhGM-CSF-mobilized PBPC transplantation: a phase III double-blind randomized trial. Bone Marrow Transplant 1997; 19:209–213.

    Article  PubMed  CAS  Google Scholar 

  59. Laughlin MJ, Kirkpatrick G, Sabiston N, Peters W, Kurtzberg J. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF. Ann Hematol 1993; 67:267–276.

    Article  PubMed  CAS  Google Scholar 

  60. Bolwell BJ, Goormastic M, Yanssens T, Dannley R, Baucco P, Fishleder A. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant. Bone Marrow Transplant 1994; 14:913–918.

    PubMed  CAS  Google Scholar 

  61. Jansen J, Thompson EM, Hanks S, et al. Hematopoietic growth factor after autologous peripheral blood transplantation: comparison of G-CSF and GM-CSF. Bone Marrow Transplant 1999; 23:1251–1256.

    Article  PubMed  CAS  Google Scholar 

  62. Pierelli L, Perillo A, Ferrandina G, et al. The role of growth factor administration and T-cell recovery after peripheral blood progenitor cell transplantation in the treatment of solid tumors: results from a randomized comparison of G-CSF and GM-CSF. Transfusion 2001; 41:1577–1585.

    Article  PubMed  CAS  Google Scholar 

  63. San Miguel JF, Hernandez MD, Gonzalez M, et al. A randomized study comparing the effect of GM-CSF and G-CSF on immune reconstitution after autologous bone marrow transplantation. Br J Haematol 1996; 94:140–147.

    Article  PubMed  CAS  Google Scholar 

  64. Powles R, Singhal S, Treleaven J, Kulkarni S, Horton C, Mehta J. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood 1998; 91:3481–3486.

    PubMed  CAS  Google Scholar 

  65. Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98:579–585.

    Article  PubMed  CAS  Google Scholar 

  66. Ayash LJ, Elias A, Hunt M, et al. Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. Br J Haematol 1994; 87:153–161.

    PubMed  CAS  Google Scholar 

  67. Locatelli F, Zecca M, Pedrazzoli P, et al. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants. Bone Marrow Transplant 1994; 13:403–410.

    PubMed  CAS  Google Scholar 

  68. Chao NJ, Schriber JR, Long GD, et al. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood 1994; 83:2823–2828.

    PubMed  CAS  Google Scholar 

  69. Lazarus HM, Goodnough LT, Goldwasser E, Long G, Arnold JL, Strohl KP. Serum erythropoietin levels and blood component therapy after autologous bone marrow transplantation: implications for erythropoietin therapy in this setting. Bone Marrow Transplant 1992; 10:71–75.

    PubMed  CAS  Google Scholar 

  70. Nemunaitis J, Singer JW, Buckner CD, et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation. Blood 1990; 76:245–253.

    PubMed  CAS  Google Scholar 

  71. Mehta J, Powles R, Singhal S, et al. Early identification of patients at risk of death due to infections, hemorrhage, or graft failure after allogeneic bone marrow transplantation on the basis of the leukocyte counts. Bone Marrow Transplant 1997; 19:349–355.

    Article  PubMed  CAS  Google Scholar 

  72. Powles R, Smith C, Milan S, et al. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial. Lancet 1990; 336:1417–1420.

    Article  PubMed  CAS  Google Scholar 

  73. Hiraoka A, Masaoka T, Mizoguchi H, et al. Recombinant human non-glycosylated granulocyte-macrophage colony-stimulating factor in allogeneic bone marrow transplantation: double-blind placebo-controlled phase III clinical trial. Jpn J Clin Oncol 1994; 24:205–211.

    PubMed  CAS  Google Scholar 

  74. Nemunaitis J, Rosenfeld CS, Ash R, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15:949–954.

    PubMed  CAS  Google Scholar 

  75. Anasetti C, Anderson G, Appelbaum FR et al. Phase III study of rhGM-CSF in allogeneic marrow transplantation from unrelated donors. Blood 1993; 82(Suppl 1): 454a (Abstr.).

    Google Scholar 

  76. Schriber JR, Chao NJ, Long GD, et al. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood 1994; 84:1680–1684.

    PubMed  CAS  Google Scholar 

  77. Hagglund H, Ringden O, Oman S, Remberger M, Carlens S, Mattsson J. A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplant 1999; 24:831–836.

    Article  PubMed  CAS  Google Scholar 

  78. Bishop MR, Tarantolo SR, Geller RB, et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000; 96:80–85.

    PubMed  CAS  Google Scholar 

  79. Przepiorka D, Smith TL, Folloder J, et al. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 2001; 97:3405–3410.

    Article  PubMed  CAS  Google Scholar 

  80. Ringdén O, Labopin M, Gorin NC, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004; 22: 416–423.

    Article  PubMed  CAS  Google Scholar 

  81. Steegmann JL, Lopez J, Otero MJ, et al. Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: results of a prospective controlled randomized trial. Bone Marrow Transplant 1992; 10:541–546.

    PubMed  CAS  Google Scholar 

  82. Klaesson S, Ringden O, Ljungman P, Lonnqvist B, Wennberg L. Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin. Bone Marrow Transplant 1994; 13:397–402.

    PubMed  CAS  Google Scholar 

  83. Biggs JC, Atkinson KA, Booker V, et al. Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Study Group. Bone Marrow Transplant 1995; 15:129–134.

    PubMed  CAS  Google Scholar 

  84. Fujimori Y, Kanamaru A, Saheki K, et al. Recombinant human erythropoietin for late-onset anemia after allogeneic bone marrow transplantation. Int J Hematol 1998; 67:131–136.

    Article  PubMed  CAS  Google Scholar 

  85. Baron F, Sautois B, Baudoux E, Matus G, Fillet G, Beguin Y. Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation. Exp Hematol 2002; 30:546–554.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Robert H. Lurie Comprehensive Cancer Center, and Division of Hematology/Oncology, Northwestern University, Chicago, IL

    Jayesh Mehta

Authors
  1. Jayesh Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, 710 N. Fairbanks Court, Olson 8256, Chicago, IL, 60611, USA

    Leonidas C. Platanias MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Mehta, J. (2005). Cytokines in Hematopoietic Stem Cell Transplantation. In: Platanias, L.C. (eds) Cytokines and Cancer. Cancer Treatment and Research, vol 126. Springer, Boston, MA. https://doi.org/10.1007/0-387-24361-5_14

Download citation

  • DOI: https://doi.org/10.1007/0-387-24361-5_14

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-24360-3

  • Online ISBN: 978-0-387-24361-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation